Caplin Steriles Ltd gets USFDA approval for Ofloxacin OTIC Solution

Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Otic Solution 0.3%, a generic therapeutic equivalent version of (RLD), FLOXIN Otic Solution of Daiichi Pharmaceuticals Inc.

Ofloxacin Otic Solution 0.3% is used as anti-infective (antibacterial) for otic (ear) use. According to IQVIATM (IMS Health), Ofloxacin Otic Solution 0.3% had US sales of approximately $36 million for the 12-month period ending June 2023.

Shares of Caplin Point Laboratories Limited was last trading in BSE at Rs. 1400.40 as compared to the previous close of Rs. 1404.55. The total number of shares traded during the day was 5396 in over 1071 trades.

The stock hit an intraday high of Rs. 1423.85 and intraday low of 1380.65. The net turnover during the day was Rs. 7537491.00.

Source : Equity Bulls

Keywords

CaplinPointLaboratories INE475E01026 CaplinSteriles FinalApproval USFDA ANDA OfloxacinOticSolution